Drug intelligence / Profile preview

efalizumab + infliximab

Development stage: Preclinical
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

A combination therapy consisting of two biologic agents: efalizumab and infliximab. Efalizumab is a humanized monoclonal CD11a-antibody that was used for treating chronic plaque psoriasis. Infliximab is a TNF-α inhibitor (monoclonal antibody) used for treating various inflammatory conditions including Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. This combination has been studied in the treatment of palmoplantar pustular psoriasis and other inflammatory conditions.

Targets

TNFA (Tumor necrosis factor alpha (soluble))ITGAL (Integrin alpha L (CD11a))

Beyond the preview

Go deeper on efalizumab + infliximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on efalizumab + infliximab.

Explore the full profile